ArticleJournal of hematology & oncology2021

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.

Heng Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.